Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effective as of July 15, 2021, Dr. Henry Esber resigned as a Director of
Bioxytran, Inc. (the "Company") for medical reasons. The Company elected Hana
Chen-Walden, currently a member of the Company's Medical Advisory Board, to fill
the vacancy created by Dr. Esber's resignation.
Dr. Hana Chen-Walden, M.D. is an Endocrinologist and has specialized in
regulatory affairs in the pharmaceutical industry in the US and Europe. Dr.
Chen-Walden has more than 35 years of regulatory experience with the EMEA and in
individual European countries. Since 2004 to present, Dr. Chen-Walden consulted
for European Clinical and Regulatory Consultancy in medical monitoring, quality
assurance and regulatory input for clinical studies in the fields of oncology,
cardiology, diabetes, neurology, respiratory diseases and medical devices. Dr.
Chen Walden received her Doctorate of Medicine from University of Tel Aviv,
Israel. Dr. Chen-Walden has practiced medicine in Germany and France. Our board
of directors believes that Dr. Chen-Walden's expertise and experience in
practicing medicine, her perspective, depth and background in medical monitoring
and quality assurance, and her leadership in regulatory affairs provide her with
the qualifications and skills to serve on our board of directors.
Compensation Arrangements with Dr. Chen-Walden
Dr. Chen-Walden is not currently receiving any compensation for her service as
member of the Company's Medical Advisory Board. She will not receive any cash
compensation as Director.
© Edgar Online, source Glimpses